Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ritonavir

FDA-approved product (solution, oral), marketed as Norvir, Ritonavir.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Ritonavir
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Chronic hepatitis C virus infection
  • Hepatitis C virus infection
  • HIV infection
  • HIV-1 infection
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Protease inhibitors
FDA pharmacologic class
Cytochrome P450 3A Inhibitor; Protease Inhibitor FDA label ↗
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AE03

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA49.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli41.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae22.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis54.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Ritonavir in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ritonavir with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Treatment of CKD Patients With HCV

    NCT07770984 · start 2026-09-15

    Registered record
    Registry ID
    NCT07770984
    Conditions
    HCV Infection ( Genotype 4) in CKD Patients
    Interventions
    SOF+DCV; OBV/PTV/r) ± ribavirin (RBV)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Not yet recruiting
    Start
    2026-09-15
    Completion
    2027-05-15
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHCV Infection ( Genotype 4) in CKD Patients
    InterventionSOF+DCV; OBV/PTV/r) ± ribavirin (RBV)
    PhasePhase 2 / Phase 3
    Registry statusNot yet recruiting

  • RECOVER-VITAL: Platform Protocol to Measure the Effects of Antiviral Therapies on Long COVID Symptoms

    NCT05595369 · start 2023-07-26

    Registered record
    Registry ID
    NCT05595369
    Conditions
    Long COVID; Long Covid19
    Interventions
    Experimental: Paxlovid 25 day dosing; Experimental: Paxlovid 15 day dosing; Placebo Comparator: Control
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2023-07-26
    Completion
    2025-03-13
    Enrolment
    963

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLong COVID; Long Covid19
    InterventionExperimental: Paxlovid 25 day dosing; Experimental: Paxlovid 15 day dosing; Placebo Comparator: Control
    PhasePhase 2
    Registry statusCompleted

  • PAxlovid loNg cOvid-19 pRevention triAl With recruitMent In the Community in Norway

    NCT05852873 · start 2023-05-12

    Registered record
    Registry ID
    NCT05852873
    Conditions
    Post COVID-19 Condition, Unspecified; SARS-CoV2 Infection; COVID-19
    Interventions
    Nirmatrelvir/ritonavir; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2023-05-12
    Completion
    2027-06-11
    Enrolment
    2,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPost COVID-19 Condition, Unspecified; SARS-CoV2 Infection; COVID-19
    InterventionNirmatrelvir/ritonavir; Placebo
    PhasePhase 3
    Registry statusActive not recruiting

  • A Study of Efficacy and Safety of Azvudine vs. Nirmatrelvir-Ritonavir in the Treatment of COVID-19 Infection

    NCT05697055 · start 2023-01-21

    Registered record
    Registry ID
    NCT05697055
    Conditions
    COVID-19
    Interventions
    Azvudine; Nirmatrelvir-Ritonavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2023-01-21
    Completion
    2023-07-21
    Enrolment
    410

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOVID-19
    InterventionAzvudine; Nirmatrelvir-Ritonavir
    PhasePhase 4
    Registry statusUnknown

  • Appropriate Evaluation of Antiviral Therapy With Nirmatrelvir-ritonavir in Hospitalized Patients

    NCT05749445 · start 2022-12-15

    Registered record
    Registry ID
    NCT05749445
    Conditions
    Hospitalized Patients
    Interventions
    Nirmatrelvir-Ritonavir
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2022-12-15
    Completion
    2023-04
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHospitalized Patients
    InterventionNirmatrelvir-Ritonavir
    PhaseNot recorded
    Registry statusUnknown

  • Relative Bioavailability Study of Nirmatrelvir/Ritonavir Oral Powder Relative to the Commercial Tablets and Estimation of the Effect of Food on Bioavailability of the Nirmatrelvir/Ritonavir Oral Powder in Healthy Participants.

    NCT05544786 · start 2022-09-28

    Registered record
    Registry ID
    NCT05544786
    Conditions
    Biological Availability
    Interventions
    Nirmatrelvir/ ritonavir; Nirmatrelvir/Ritonavir; Nirmatrelvir/Ritonavir; Nirmatrelvir/ritonavir; Nirmatrelvir/ritonavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2022-09-28
    Completion
    2022-11-29
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBiological Availability
    InterventionNirmatrelvir/ ritonavir; Nirmatrelvir/Ritonavir; Nirmatrelvir/Ritonavir; Nirmatrelvir/ritonavir +1 more
    PhasePhase 1
    Registry statusCompleted

  • Efficacy and Safety Evaluation of Paxlovid for COVID-19: a Real-world Case-control Study

    NCT05532852 · start 2022-07-01

    Registered record
    Registry ID
    NCT05532852
    Conditions
    COVID-19 Pneumonia
    Interventions
    standard-of-care plus Paxlovid; standard-of-care
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2022-07-01
    Completion
    2023-10
    Enrolment
    728

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOVID-19 Pneumonia
    Interventionstandard-of-care plus Paxlovid; standard-of-care
    PhaseNot applicable
    Registry statusUnknown

  • Evaluation of SSD8432 and Ritonavir in Adult Subjects With COVID-19 Clinical Study

    NCT05373446 · start 2022-05-20

    Registered record
    Registry ID
    NCT05373446
    Conditions
    COVID-19
    Interventions
    SSD8432 300mg; SSD8432 750mg; SSD8432Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2022-05-20
    Completion
    2023-03-31
    Enrolment
    72

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOVID-19
    InterventionSSD8432 300mg; SSD8432 750mg; SSD8432Placebo
    PhasePhase 2
    Registry statusUnknown

  • Once Daily Dosing of Lonafarnib Co-administered With Ritonavir for Treatment of Chronic Hepatitis D Virus Infection

    NCT05229991 · start 2021-05-15

    Registered record
    Registry ID
    NCT05229991
    Conditions
    Hepatitis D, Chronic
    Interventions
    Lonafarnib; Ritonavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2021-05-15
    Completion
    2025-02-05
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis D, Chronic
    InterventionLonafarnib; Ritonavir
    PhasePhase 3
    Registry statusCompleted

  • Open Multicentre Study of the Safety and Efficacy Against COVID-19 of Nirmatrelvir/Ritonavir in the Adult Population

    NCT05601167 · start 2021-02-17

    Registered record
    Registry ID
    NCT05601167
    Conditions
    COVID-19
    Interventions
    nirmatrelvir/ritonavir; Standard of care
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2021-02-17
    Completion
    2022-06-01
    Enrolment
    264

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOVID-19
    Interventionnirmatrelvir/ritonavir; Standard of care
    PhasePhase 3
    Registry statusCompleted

  • Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19

    NCT04542694 · start 2020-05-21

    Registered record
    Registry ID
    NCT04542694
    Conditions
    COVID-19
    Interventions
    Favipiravir; Standard of care
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2020-05-21
    Completion
    2020-08-20
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOVID-19
    InterventionFavipiravir; Standard of care
    PhasePhase 3
    Registry statusCompleted

  • An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial

    NCT04343768 · start 2020-04-09

    Registered record
    Registry ID
    NCT04343768
    Conditions
    COVID-19
    Interventions
    Hydroxychloroquine; Lopinavir / Ritonavir; Interferon Beta-1A; Interferon Beta-1B
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2020-04-09
    Completion
    2020-04-27
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOVID-19
    InterventionHydroxychloroquine; Lopinavir / Ritonavir; Interferon Beta-1A; Interferon Beta-1B
    PhasePhase 2
    Registry statusCompleted

  • Corona Virus Disease 2019 Patients Whose Nucleic Acids Changed From Negative to Positive

    NCT04333589 · start 2020-04-01

    Registered record
    Registry ID
    NCT04333589
    Conditions
    COVID-19
    Interventions
    Favipiravir
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2020-04-01
    Completion
    2020-09-15
    Enrolment
    210

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOVID-19
    InterventionFavipiravir
    PhaseNot applicable
    Registry statusUnknown

  • Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection

    NCT04261907 · start 2020-02-11

    Registered record
    Registry ID
    NCT04261907
    Conditions
    2019-nCoV
    Interventions
    ASC09/ritonavir group; lopinavir/ritonavir group
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2020-02-11
    Completion
    2020-04-13
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    Condition2019-nCoV
    InterventionASC09/ritonavir group; lopinavir/ritonavir group
    PhaseNot applicable
    Registry statusTerminated

  • Bioequivalence Study of GP30101 800 mg (GEROPHARM) Versus PREZISTA® 800 mg ("Jonson&Jonson", Russia)

    NCT04268472 · start 2019-06-06

    Registered record
    Registry ID
    NCT04268472
    Conditions
    Bioequivalence
    Interventions
    GP30101; Prezista®; GP30101; Prezista®
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2019-06-06
    Completion
    2019-09-06
    Enrolment
    44

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBioequivalence
    InterventionGP30101; Prezista®; GP30101; Prezista®
    PhaseNot applicable
    Registry statusCompleted